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Abstract
Background: Influenza is an acute viral infection of the respiratory tract. A rapid confirmatory diagnosis of influenza
is important, since it is highly transmissible and outbreaks of influenza within the hospital setting increase morbidity
and mortality. The objective of this study was to evaluate the cost implications, from the perspective of the UK
NHS, of using on-label nasal swabs with the Alere™ i Influenza A & B test in a near patient setting.
Methods: A cost consequence model was developed. The time horizon of the model was from hospital admission
on suspicion of influenza until the end of treatment (following a diagnosis of influenza or discharge from hospital).
Data on the prevalence of influenza and the sensitivity and specificity of the Alere™ i Influenza A & B test came
from two prospective observational diagnostic accuracy studies. Costs were obtained from published resources.
Uncertainties in the model data were investigated using deterministic, one-way sensitivity analyses.
Results: Using the Alere™ i Influenza A & B point of care test with nasal swabs (on label) in NHS medical
assessment units and emergency departments could save approximately £242,730 per 1000 adults presenting with
influenza-like symptoms. The main cause for this was reduced times to availability of the result compared with the
laboratory RT-PCR test. Other key drivers of savings were the cost of isolation, the prevalence of influenza, the
specificity of the test, and the availability of isolation resources.
Conclusions: The Alere™ i Influenza A & B point of care test would have greatest impact in hospitals that have
extensive delays in the time to receive a result. Sensitivity analyses identified the model parameters which would have
greatest effect on the result and confirmed that assumptions were conservative, i.e. did not change key results.
Keywords: Near-patient testing, Point-of-care testing, Influenza, Flu, Alere™ i Influenza A & B test, Cost analysis,
Cost consequences, Cost minimisation, Infection control
Background
Influenza (flu) is a contagious viral disease that can cause
mild to severe illness. Risk factors for severe complications
from influenza include pregnancy, old age, and long-term
conditions that impair body’s defence systems [1, 2]. Influ-
enza is easily transmitted in healthcare environments. Key
to preventing its transmission in such settings is rapid diag-
nosis and prompt initiation of drug treatment [3] and
infection control procedures, which ideally include isolation
precautions for admitted patients, as well as barrier nursing.
A recent study in the UK, conducted at three sites
with on-site laboratories and one with an off-site labora-
tory, estimated that the median time for a swab to be
taken and a result to be returned from standard respira-
tory virus testing was 1.2 days after a patient was admit-
ted [4]. With delays such as this, clinicians must make
initial management decisions based on clinical signs and
symptoms, and then wait for the laboratory results to
finalise the diagnosis and adjust management [1].
Similarities between the clinical features of influenza
and other respiratory viruses make clinical diagnosis
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unreliable: the sensitivity of clinical judgement has been
shown to be as low as 27% when compared to polymer-
ase chain reaction (PCR)-based tests [5].
Rapid, accurate diagnostic tests for influenza, highlighted
as a priority for diagnostic test development by the World
Health Organization, allows influenza to be managed
according to test results and avoids the empiric use of anti-
biotics in patients with influenza [6]. Rapid influenza anti-
gen detection tests are popular point of care tests due to
their ease of use and ability to provide a result within 15 to
30 min. However, their sensitivities tend to be low (ranging
from 10 to 70%), meaning that they are not useful at
excluding influenza [7]. Direct fluorescent antibody assays
are more sensitive and can provide a result within 3 h, but
require skilled laboratory staff. Rapid PCR-based nucleic
acid amplification tests (NAATs) have been developed with
equivalent sensitivity to real-time reverse transcriptase PCR
(RT-PCR) and can identify influenza with a turnaround
time of less than 75 min. However, they need to be per-
formed in a laboratory [8].
The Alere™ i Influenza A & B near patient test (Alere
flu NPT) uses isothermal nicking-enzyme amplification
technology (NEAR) to provide a result within 15 min. A
recent clinical evaluation of the Alere flu NPT with
cohorts from four UK NHS adult medical assessment
units (MAUs) and accident and emergency departments
(A&Es) compared it with RT-PCR performed by a ser-
vice laboratory. Following established practice, the study
used off-label throat swabs in place of on-label nasal or
nasopharyngeal swabs. The study concluded that, with
the Alere flu NPT’s high specificity of 96.8% (95% confi-
dence interval (CI) 95.2 to 98.3%) for combined influ-
enza A and B, its use could generate substantial savings
by optimising the management of patients admitted to a
medical assessment unit with possible influenza. This
finding provides motivation for the current study.
Further to the above, Davis et al. [4] found that the
sensitivity of the Alere flu NPT was 75.8%, CI 67.0 to
84.6%. This is notably lower than that found in an
American multicentre cohort study of the Alere flu
NPT: sensitivity 97.8%, CI 91.6 to 99.6% for influenza A
and sensitivity 91.8%, CI 82.4 to 96.6% for Influenza B,
when compared with viral cell culture [9]. This study
used RT-PCR to resolve discrepancies which resulted in
improved diagnostic accuracy measures: sensitivity
99.8%, CI 96.8 to 100% for influenza A and sensitivity
98.1%, CI 99.3 to 97.0% for Influenza B. It was suggested
that the difference in sensitivities was due to differences
in sample collection: throat swabs (off-label) in the UK
study and nasal swabs (on-label) in the American study.
The high sensitivity with nasal swabs was confirmed in a
recent prospective evaluation comparing the Alere flu
NPT with another commercially available rapid isother-
mal NAAT [10]. The two studies providing data on test
accuracy for the model were all assessed as low risk of
bias [11].
Two of the centres involved in the UK clinical evalu-
ation have since adopted the Alere flu NPT test using
throat swab samples. Because the sensitivity was found
to be low for this sample type, patients with a negative
Alere flu NPT test are also tested for influenza with the
service laboratory RT-PCR assay. This raises the ques-
tion about clinical outcomes and potential cost savings if
the test were to be used with nasal swabs, without sup-
plementary service laboratory testing for negative tests.
We addressed this question by modelling the clinical
outcomes and budget impact of the standard care path-
way and pathways using the Alere flu NPT with throat
swabs or nasal swabs.
Methods
Suspected influenza was defined as a fever ≥ 37.8 °C and
at least one influenza-like symptom: headache, extreme
tiredness, dry cough, sore throat, runny or stuffy nose,
and muscle pain [4].
The costs associated with the diagnosis and manage-
ment of influenza were modelled for a hypothetical
cohort of 1000 patients (adults and children) with sus-
pected influenza. Costs were estimated from the per-
spective of the UK NHS. The cohort size was chosen so
the model’s results can easily be extrapolated for actual
NHS hospitals.
The total cost of a testing strategy includes the cost of
isolation, the cost of antiviral prescribing, and the cost
of prophylactic treatment of other patients exposed to
patients being treated for influenza. Costs are presented
in pounds sterling for 2017.
Design of the cost consequence model
A decision-analytic model, shown in Fig. 1, was developed
in TreeAge Pro 2009 (© 2018 TreeAge Software Inc.,
Williamstown, MA, USA). For quality assurance, the
analysis was also carried out using R (© 2004–2016, The R
Foundation for Statistical Computing, Vienna, Austria).
The time horizon of the model is the acute episode of
suspected influenza and its directly associated costs, and
thus no discounting was needed.
Three strategies for diagnosing influenza were compared:
Strategy 1: service laboratory RT-PCR testing for influenza
(current practice, and base case for comparisons)
Patients with suspected influenza in a hospital setting
are investigated and treated according to the hospital’s
local protocol, which will include guidance on the use of
isolation measures according to availability and clinical
judgement of need.
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Strategy 2: Alere™ i Influenza A & B near patient test (new
test, nasal swabs, higher sensitivity)
Following presentation with suspected influenza, the deci-
sion about treatment and isolation (subject to resource
availability) is made according the result of the Alere flu
NPT. A patient who is isolated based on a positive result
of a near patient test will be removed from isolation when
their symptoms resolve. For true positive patients, this has
been estimated to be 5 days; however, for those patients
with a false positive test, the duration of their symptoms is
likely to be shorter, and we estimated this as 3 days.
Strategy 3: Alere™ i Influenza A & B near patient test (new
test, throat swabs, lower sensitivity)
Following presentation with suspected influenza, the deci-
sion about treatment and isolation (subject to resource avail-
ability) is made according the result of the Alere flu NPT.
People who test negative are tested with RT-PCR by the ser-
vice laboratory. A patient who has tested negative for flu
with the Alere flu NPT, who later receives a positive diagno-
sis for flu with the RT-PCR test (i.e. a false negative result for
the NPT), will be isolated for the duration of the symptoms.
As the full duration of isolation for a positive flu patient is
5 days and the RT-PCR result is returned within 3 days, the
length of stay in isolation is estimated to be 2 days.
Quantifying the model’s parameters
The data used for the model and their sources are
shown in Table 1. PUBMED and NICE Evidence Search
were used to identify health technology assessments with
data relevant to the UK. When relevant data were not
available in the published literature or datasets, we
obtained the opinions of experts involved in the UK
clinical evaluation of the Alere flu NPT [4].
Diagnostic accuracy data for Strategy 2, in which nasal
swabs were used for the Alere flu NPT, were obtained
from a study conducted in the USA. This study
compared the influenza A result from the Alere flu NPT
to culture. Because no diagnostic accuracy data were
available for Influenza B, the model extrapolated the
sensitivity and specificity results from influenza A to
influenza B.
The effectiveness of antiviral treatment is greatest if
started within 48 h of the onset of symptoms [12]. Con-
sequently, the model assumes that patients with fewer
than 48 h of symptoms would receive antiviral treatment
for 5 days if the RT-PCR was positive, or 3 days (the
average time to RT-PCR result) if it was negative.
When published information was not available,
estimates were provided by NHS clinicians, with expertise
in the field of infectious disease and who were
co-investigators in a recent UK clinical evaluation of the
Alere flu NPT [4]. Estimates were obtained this way for
the costs of antiviral treatment, the costs of isolation, the
cost associated with prophylactic treatment of patients
exposed to a patient with influenza (to prevent developing
a nosocomial infection), and the probabilities of outcomes
such as onward transmission. The cost of a transmission
Fig. 1 Model structure: RT-PCR testing compared with Alere flu NPT nasal and throat swab testing
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associated with a false negative Alere flu NPT result was
estimated as the combined cost of isolation and antiviral
treatment.
Sensitivity analyses to explore uncertainties in the
model’s outcomes
A series of sensitivity analyses explored the effects of un-
certainties in the model’s assumptions on the model’s out-
comes. One-way sensitivity analyses were carried out for
each of the parameters in Table 1. The effects on patient
management costs were explored in sensitivity analyses
that omitted influenza testing costs. Other sensitivity ana-
lyses explored uncertainties resulting from applying the
US data to NHS adult MAUs and A&Es. The proportion
of people presenting more than 48 h after the onset of
symptoms was not included in the sensitivity analysis (or
model) since the only difference to the model’s results
would be in the cost of oseltamivir which is 1.7% the cost
of isolation, and therefore negligible.
Because there was no evidence or expert opinion available
on the minimum and maximum values to employ in the
sensitivity analysis of isolation cost (Table 1), this parameter
was varied from 50 to 150%, a range that encompasses the
differences in isolation costs at different facilities.
The prevalence of influenza (Table 1) was varied
from that observed in the clinical evaluation (base
case) to a minimum of 0 (corresponding to the start
and end of the influenza season) and a maximum of
0.4 (corresponding to the peak of the seasonal epi-
demic in the UK). The upper limit is above the
highest average single prevalence observed during the
clinical evaluation of the Alere™ i Influenza A & B
near patient test in four UK hospitals during the
2014/2015 influenza season [4].
The base case probability of onward transmission of
nosocomial infection (Table 1) was provided by ex-
perts. The range used for the sensitivity analysis of
transmission probability was from 0 (e.g. all high-risk
patients exposed to influenza are vaccinated, have
sufficient immunity, and therefore do not contract in-
fluenza) to 0.4 (if not all high-risk patients are vacci-
nated, some may contract influenza when exposed to
patients with it).
The length of patient stay without confirmed influ-
enza (Table 1) was varied for the sensitivity analysis
from 1 to 5 days (i.e. 2 days around the base case
assumption of 3 days). The lower limit represents the
scenario in which a patient, despite suspicion of influ-
enza, is not sufficiently unwell to be admitted to a
ward and is simply sent home. The upper limit
accounts for patients who do not have influenza, but
return of influenza testing results is delayed.
The sensitivity and specificity of the Alere flu NPT test
with both nasal (on label) and throat (off label) swabs
were also varied for the sensitivity analysis by 10% in
either direction.
For all parameters, the Alere flu NPT testing with
both swab types results in cost savings across the
ranges used in the sensitivity analyses when compared
with RT-PCR testing.
Table 1 Model parameters and data sources
Parameter for the model Base case value Data source
Number of participants in study 1000
Sensitivity of NPT with nasal swabs 0.98 Bell et al. [9]
Specificity of NPT with nasal swabs 0.86 Bell et al. [9]
Sensitivity of NPT with throat swabs 0.76 Davis et al. [4]
Specificity of NPT with throat swabs 0.97 Davis et al. [4]
Prevalence of influenza 0.17 Bell et al. [9]
Length of stay, influenza diagnosed (days) 5.00 Duration of antiviral treatment
Length of stay, influenza not diagnosed (days) 3.00 Av days to PCR result
Cost of NPT test 23.45 Estimate
Cost of RT-PCR 70.00 Estimate
Cost of full isolation
(Cost of partial isolation = cIsol/2)
88.43 Health Protection Scotland [14]
Cost per dose of 75 mg oseltamivir (taken every 12 h) 1.54 MIMS [15]
Cost of nosocomial infection 2*(cOseltamivir * 2 * RxOseltamivir + cIsol*los) NICE guidance [1]
Number of days for oseltamivir treatment 5.00 MIMS [15]
Probability of isolation if influenza detected 1.00 Expert opinion
Probability of isolation if influenza not detected 0.00 Expert opinion
Probability of nosocomial infection 0.20 Expert opinion
Allen et al. Diagnostic and Prognostic Research  (2018) 2:15 Page 4 of 8
Results
Overall, Strategy 2, Alere flu NPT testing with nasal
swabs (on label), is estimated to provide total savings
over £242,730 for a cohort of 1000 patients with
influenza-like symptoms (Table 2). Strategy 3, using the
Alere flu NPT with throat swabs (off label), is less costly
than current practice, with total savings of £211,857.
The cost components that drive these potential savings
and the results of sensitivity analyses exploring the
effects of the uncertainties in the model parameters are
described in the following sections.
Isolation costs
In Strategy 1, the RT-PCR testing pathway, all 1000
patients are presumptively isolated at a total cost of
£295,356 before results become available. With the
prevalence of influenza being 17% (an approximate average
over the winter epidemic), only 170 of these patients would
have flu, meaning that 830 would be isolated unnecessarily
for 3 days while waiting for the RT-PCR result. The cost of
this would be £220,190. With Strategies 2 and 3, Alere flu
NPT testing, only those who test positive would be isolated.
The total cost for the cohort is £104,489 for Strategy 2
(using nasal swabs) and £71,298 for Strategy 3 (using throat
swabs), giving savings on this line item of £190,867 and
£231,334 respectively. The savings are higher for Strategy 3
(using throat swabs) due to the greater number of false
negative results (Strategy 2: Fn = 3, Strategy 2: Fn = 41).
Influenza testing costs
The total costs for testing for influenza in Strategies 1
and 2 (RT-PCR and Alere flu NPT with nasal swabs) are
£70,000 and £23,450 respectively. In Strategy 3 (Alere
flu NPT using throat swabs), patients who test negative
on the NPT are also tested for influenza using the
laboratory RT-PCR at an additional cost of £59,120.
Prescribing costs
With Strategy 1 (testing with RT-PCR), assuming that
the prevalence of influenza is 17%, 830 people would
receive antiviral treatment unnecessarily, at a cost of
£7674 (i.e. influenza-negative patients receiving antiviral
treatment until a negative test result). With Strategies 2
and 3, Alere flu NPT testing, only those who test
positive receive antivirals. Of those testing positive in
the nasal swab and throat swab pathways, 116 and 27
patients would have false positive results and they would
receive unnecessary antiviral treatment costing £1788
and £416, respectively. Strategy 3, NPT testing with
throat swabs, provides greater savings because the
specificity is greater than when using throat swabs.
Onward transmission costs
All patients in Strategy 1, RT-PCR testing, are presump-
tively isolated and therefore there are no costs associated
with the onward transmission of the virus to other pa-
tients. For Strategies 2 and 3, Alere flu NPT testing, the
nasal swab and throat swab tests are not 100% sensitive:
3 and 41 patients, respectively, would receive a false
negative diagnosis. The people initially considered as
negative would not be isolated and could have infected
other patients. The costs associated with this onward
transmission for a cohort of 1000 patients are £622 when
nasal swabs are used (Strategy 2) but is substantially
higher at £7529 when throat swabs are used (Strategy 3).
Sensitivity analyses
Table 3 ranks the parameters by the range in cost savings,
from highest to lowest for both swab types. Varying the
average length of stay with in-patients with influenza-like
symptoms, who are later confirmed to not have influenza,
gives the largest change in cost savings: £262,718 for
Strategy 2, Alere flu NPT with nasal swabs, and £308,977
for Strategy 3, Alere flu NPT with throat swabs. The next
most influential parameters for both swab types are, in
decreasing order, the cost of isolation and the probability
of isolation in patients who have a positive influenza test.
Varying the prevalence of influenza results in the same
range of savings for both swab types. Varying the Alere flu
NPT specificity has a larger effect on savings than
varying the sensitivity for both swab types. However,
the probability of nosocomial infection has negligible
Table 2 Cost analysis of the RT-PCR and Alere™ i Influenza A & B near patient testing strategies for patients with suspected
influenza. Cells with italicized text identify the NPT testing strategy that provides the lowest cost and maximum saving for that line
item
Costs per cohort of 1000 patients
Test RT-PCR Alere flu NPT with: Maximum saving
Cost of: Nasal swab Throat swab
Isolation £295,356 £104,489 £71,298 £231,334
Influenza testing £70,000 £23,450 £82,571 £46,550
Antiviral treatment £10,294 £4357 £2395 £7898
Nosocomial infection £0 £622 £7529 − £622
Total cost £375,650 £132,919 £163,793 £242,730
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effects on the savings when nasal swabs are used and
a larger effect when throat swabs are used.
Due to the low sensitivity of the Alere flu NPT when
throat swabs are used, a clinician may choose not to
remove a patient from isolation until a negative RT-PCR
result is obtained. In this scenario, the cost of isolation for
Strategy 3, Alere flu NPT with throat swab, would be the
same as that for Strategy 1, RT-PCR testing (£295,365 for
cohort of 1000 patients), and would be the most costly
strategy overall (£380,321 for a cohort of 1000 patients).
Our analysis assumes that all patients suspected of in-
fluenza would be isolated. However, in practice, isolation
resources are limited and their availability can change
over the course of an epidemic, e.g. when wards are
temporarily allocated for the sole use of patients with
influenza (“cohorting”). Sensitivity analysis found that iso-
lation rates between 0 and 1 had a substantial effect on
the cost savings made possible with the use of the Alere™ i
Influenza A & B near patient test. When the probability of
isolation was low, e.g. when isolation resources are ex-
tremely limited, savings from using the Alere flu NPT
with both swab types were predicted to be modest (£5936
for nasal swabs and £623 for throat swabs).
Discussion
When a patient is admitted to A&E or MAU for suspect
influenza, the standard practice in the UK NHS is to
confirm the diagnosis with RT-PCR test for influenza.
This testing strategy was compared in a decision model
with approaches that employ the Alere™ i Influenza A & B
near patient test used with either throat swabs (off-label,
but common practice in the UK NHS) or nasal swabs
(on-label, and usual practice in the USA). The reason
given by NHS clinicians for preferring throat swabs is that
nasal swabs are more uncomfortable for patients and
more difficult for clinicians. Our modelling methods
followed (with some minor modifications) the guidelines
published by the International Society For Pharmacoeco-
nomics and Outcomes Research [13]. Sensitivity analyses
were designed to include the range of parameter values
relevant to decision makers in the UK NHS.
The Alere flu NPT was found to save costs compared
to service laboratory RT-PCR testing, regardless of swab
type used. However, the cost savings are slightly greater
when nasal swabs (on label) are used. This is primarily
due to the higher sensitivity with nasal swabs, as found
in previous clinical evaluations [9, 10].
The greatest impact on costs comes from reducing the
time to availability of the result and the subsequent in-
creased accuracy in employing isolation measures and
prescribing antivirals.
The lower sensitivity of the Alere flu NPT used with
(off label) throat swabs resulted in the model predicting
a larger number of patients with false negative test
Table 3 Univariate sensitivity analysis showing the savings (when compared to RT-PCR testing) for the minimum and
maximum values of each parameter. Top panel: Strategy 2, NPT testing with nasal swabs. Bottom panel: Strategy 3, NPT
testing with throat swabs
Savings (min value of parameter) Savings (max value of parameter) Savings range
Strategy 2. NPT testing with nasal swabs
Length of stay no flu (1–5) £64,822 £327,540 £262,718
Isolation cost (£44.22–£132.65) £100,747 £291,615 £190,867
Probability of isolation with flu (0–1) £5936 £196,181 £190,245
Prevalence (0–0.4) £165,067 £238,276 £73,210
Specificity nasal swabs (0.7–0.96) £172,883 £219,479 £46,596
Sensitivity nasal swabs (0.8–1) £200,848 £195,248 £5601
Probability of nosocomial infection (0–0.4) £196,803 £195,559 £1245
Length of stay with flu (3–7) £195,580 £196,782 £1203
Strategy 3. NPT testing with throat swabs
Length of stay no flu (1–5) £69,939 £378,916 £308,977
Isolation cost (44.215–132.645) £112,399 £336,457 £224,059
Probability of isolation with flu (0–1) £623 £224,428 £223,805
Prevalence (0–0.4) £193,314 £266,523 £73,210
Specificity throat swabs (0.7–1) £201,596 £231,883 £30,288
Probability of nosocomial infection (0–0.4) £231,957 £216,898 £15,059
Sensitivity throat swabs (0.8–0.86) £226,055 £222,734 £3321
Length of stay with flu (3–7) £224,428 £224,428 £0
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results, who would not be treated or isolated until the
laboratory results became available, with the result that
influenza would be transmitted to other patients.
The model assumes that isolation precautions are not
used for patients who test negative for flu. Although isola-
tion measures would be indicated for some of these
patients, in the A&E and MAU this is a rare occurrence
and would have negligible effects on the model’s outcomes.
The assumptions made in the model are conservative,
i.e. making its structure more sophisticated would be
unlikely to change conclusions drawn from its results.
For example, the operational definition of “possible
influenza” had a low threshold for including people with
increased respiratory symptoms and chronic heart
failure or chronic obstructive pulmonary disease.
Limitations
The data in our analysis are from observational studies.
The results therefore indicate what could be achieved if
tests are used and results applied as modelled. A rando-
mised controlled interventional study would be able to
assess if the model’s assumptions translate into reality.
(Given the cost of the research and the growing adoption
of rapid point tests, such research is unlikely to happen.)
Our analysis considers facility-specific costs over a
relatively short time horizon. This choice was made in
order to assess the costs directly associated with the
admission of a patient with suspected influenza, and
does not take into account costs or benefits associated
with other possible reasons for admission. Costs of
complications (e.g. costs of extended inpatient stay or
higher levels of care) were not included. The costs are
high, but infrequently incurred. Omitting the costs of
complications from the model is conservative, in that their
exclusion biases results in favour of the less sensitive test
method, throat swabbing, since differences in costs would
come from differences in onward transmission from
patients with flu who were not isolated.
The main structural limitations in the model are the
simplification of the effects of transmitting influenza,
not including other testing strategies for comparison,
and not taking account of patients with an influenza-like
illness who would be isolated even if they test negative
for flu. However, it would have been outside the aims
and resources of this project to extend its scope, for
example to the public health goal of limiting the spread
of infection.
A probability sensitivity analysis (PSA) was not con-
ducted as it was outside the available resources for this
project. The main drivers of savings identified in the
one-way exploratory sensitivity analysis were reduced
times to availability of the result, cost of isolation, preva-
lence of influenza, specificity of the test, and the
availability of isolation resources, and it seems unlikely
that a PSA would have changed the study’s conclusions.
Conclusions
The higher sensitivity when using the Alere™ i Influenza
A & B test with (on label) nasal swabs has the potential
to increase savings for MAUs and A&Es in the UK NHS
and, importantly, reduce onward transmission of influ-
enza. Future research should repeat the diagnostic
performance evaluation for the Alere™ i Influenza A & B
near patient test using both nasal and throat swabs in
the same cohort. This would, of course, involve address-
ing the issue of obtaining informed consent and ethical
approval for multiple swabbing of the same patient.
Future research should also evaluate outcomes from
the short time to result with a rapid influenza such as
the potential for earlier antiviral use, fewer antibiotics
for patients with confirmed influenza, reduction of
unnecessary investigations, more appropriate discharge
of patients, and potential harms.
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